Has Danny Meslemani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,244 in general payments to Danny Meslemani, MD across 293 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Danny Meslemani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Danny Meslemani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Danny Meslemani, MD

Otolaryngology · Melville, NYNPI 1447460134

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.9% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Neurent Medical Limited at 42.4% of the total. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,244in general payments, 2019–2025

Across 293 payments — averaging $55.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurent Medical Limited$7K
Aerin Medical Inc.$4K
Stryker$1K
GSK$783
Sanofi$659
Regeneron Healthcare Solutions, Inc.$658
plus $2K from 21 others

What the payments were for

Consulting fees$1001%
Travel & lodging$6674%
Food & beverage$15,41995%
Education$580%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurent Medical Limited	61	$6,884
Aerin Medical Inc.	47	$3,524
Stryker	16	$1,450
GSK	36	$783
Sanofi	16	$659
Regeneron Healthcare Solutions, Inc.	32	$658
Optinose US, Inc.	26	$429
Spirair, Inc.	1	$248
Arrinex, Inc.	2	$190
Amgen	6	$169
Hikma Pharmaceuticals USA	7	$168
Medtronic	4	$163
Alk-abello, Inc	7	$131
Kaleo, Inc.	6	$123
Intersect ENT, Inc.	2	$121
Integra Lifesciences Corporation	3	$96
Acclarent, Inc	4	$86
Novartis	4	$85
AstraZeneca	3	$66
ARS Pharmaceuticals Operations, Inc.	2	$43
Phadia US Inc.	2	$34
AbbVie	1	$31
Pfizer	1	$23
Incyte Corporation	1	$22
Biocryst US Sales Co., LLC	1	$21
Acelrx Pharmaceuticals, Inc.	1	$20
Genentech USA, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NEUROMARK Radiofrequency Console$5,480
NEUROMARK Device$4,325
VIVAER STYLUS$2,009
NEUROMARK System$1,491
RHINAER STYLUS$1,271
SeptAlign$496
TURBALIGN$496
ENTELLUS - ENTELLUS MEDICAL SHAVER SYSTEM$406
CLARIFIX$389
NEUROMARK Radiofrequency Generator$336
ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM$270
DUPIXENT$239
ENTELLUS - MINIFESS SURGICAL INSTRUMENT SETS$143
ENTELLUS - MINIFESS MAXILLARY SEEKERS$135
CONSUMABLES$133
FOCESS HD WIRELESS CAMERA$114
SHAVER SYSTEM$114
ENTELLUS - XPRESS ENT DILATION SYSTEM$113
CHROMOPHARE$110
PROPEL$100

How this compares

$16,244 in reported general payments places this provider in the 90th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York →

Medicare billing

Part B allowed, 2024

$530,473

Medicare patients

645

Services billed

2,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Olopatadine Hcl	99	$8,178
Mometasone Furoate	116	$6,277
Ipratropium Bromide	223	$4,967
Azelastine Hcl	151	$3,894
Fluticasone Propionate	174	$1,649
CefuroximeCefuroxime Axetil	45	$954
Flunisolide	15	$586
Fluocinolone Acetonide Oil	13	$552
Montelukast Sodium	58	$542
Mupirocin	64	$396
Doxycycline Monohydrate	35	$383
Pantoprazole Sodium	23	$288
Levocetirizine Dihydrochloride	45	$279
Acetic Acid	16	$244
Prednisone	37	$174

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Melville

Robert KellmanSyracuse$2.5M
Roheen RaithathaNew York$830K
Nora PerkinsAlbany$300K
Moshe EphratNew Hyde Park$250K
Gavin SetzenAlbany$243K
Habibullah JamalRye Brook$179K
Albert JenFlushing$171K
Dennis KrausNew York$159K
Nitin BhatiaWhite Plains$120K
Sveta KarelskyRochester$101K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →